{
    "eid": "2-s2.0-85064041029",
    "title": "Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice",
    "cover-date": "2019-04-05",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Virology",
            "@code": "2406",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Dyslipidemia",
        "HIV",
        "Resource limited setting",
        "Rilpivirine",
        "Switching"
    ],
    "authors": [
        "Sivaporn Gatechompol",
        "Anchalee Avihingsanon",
        "Tanakorn Apornpong",
        "Win Min Han",
        "Stephen J. Kerr",
        "Kiat Ruxrungtham"
    ],
    "citedby-count": 2,
    "ref-count": 24,
    "ref-list": [
        "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators",
        "Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study",
        "Life expectancy after initiation of combination antiretroviral therapy in Thailand",
        "Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review",
        "Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials",
        "Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies",
        "Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials",
        "Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women",
        "Impact of food and different meal types on the pharmacokinetics of rilpivirine",
        "Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study",
        "Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study",
        "Switching to coformulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: data from a multicenter cohort",
        "Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks",
        "Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants",
        "Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens",
        "Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy",
        "Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients",
        "Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project",
        "Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis",
        "Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management",
        "Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Thai Red Cross AIDS Research Centre",
        "Thailand Research Fund"
    ]
}